一分钟看懂
这是一项关于多发性骨髓瘤的I 期 / II 期研究，登记的药物或干预包括Sonrotoclax；Dexamethasone；Carfilzomib；Daratumumab；Pomalidomide，当前状态为招募中。登记地点显示中国北京、重庆、福州、厦门等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sonrotoclax；Dexamethasone；Carfilzomib；Daratumumab；Pomalidomide · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University Third Hospital · 北京
- Beijing Chao Yang Hospital · 北京
- Peking University Peoples Hospital · 北京
- Chongqing Cancer Hospital · 重庆
- Fujian Medical University Union Hospital · 福州
- The First Affiliated Hospital of Xiamen University · 厦门
- Sun Yat Sen University Cancer Center · 广州
- The Second Hospital of Hebei Medical University · 石家庄
- Henan Cancer Hospital · 郑州
- The First Affiliated Hospital of Zhengzhou University · 郑州
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology · 武汉
- Hunan Cancer Hospital · 长沙
- Jiangsu Province Hospital · 南京
- The First Affiliated Hospital of Nanchang University Branch Xianghu · 南昌
- The First Hospital of China Medical University · 沈阳
- Qingdao Municipal Hospital · 青岛
- Affiliated Zhongshan Hospital of Fudan University · 上海
- Shanghai Fourth Peoples Hospital Affiliated to Tongji University · 上海
- Tianjin Medical University General Hospital · 天津
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch · 天津
- The First Affiliated Hospital, Zhejiang University School of Medicine · 杭州
公开的入选条件
- 1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- 2. A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine)
- 3. Measurable disease defined as:
- i. M-spike ≥ 500mg/dL, or ii. Urine protein M-spike of ≥ 200 mg/day, or iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio
- 4. Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy.
- i. Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy but does not meet the criteria for refractory MM.
- ii. Refractory MM is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy or progresses within 60 days of last therapy.
- 1. In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04973605；登记信息更新于 2026-09-14。